AU2014243925B2 - Method of enhancing delivery of therapeutic compounds to the eye - Google Patents

Method of enhancing delivery of therapeutic compounds to the eye Download PDF

Info

Publication number
AU2014243925B2
AU2014243925B2 AU2014243925A AU2014243925A AU2014243925B2 AU 2014243925 B2 AU2014243925 B2 AU 2014243925B2 AU 2014243925 A AU2014243925 A AU 2014243925A AU 2014243925 A AU2014243925 A AU 2014243925A AU 2014243925 B2 AU2014243925 B2 AU 2014243925B2
Authority
AU
Australia
Prior art keywords
plasmin
retinal
cell
eye
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014243925A
Other languages
English (en)
Other versions
AU2014243925A1 (en
Inventor
Elena Ivanova
Zhuo-Hua Pan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wayne State University
Original Assignee
Wayne State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne State University filed Critical Wayne State University
Publication of AU2014243925A1 publication Critical patent/AU2014243925A1/en
Application granted granted Critical
Publication of AU2014243925B2 publication Critical patent/AU2014243925B2/en
Priority to AU2019201474A priority Critical patent/AU2019201474A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2014243925A 2013-03-14 2014-03-13 Method of enhancing delivery of therapeutic compounds to the eye Ceased AU2014243925B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019201474A AU2019201474A1 (en) 2013-03-14 2019-03-04 Method of enhancing delivery of therapeutic compounds to the eye

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361785015P 2013-03-14 2013-03-14
US61/785,015 2013-03-14
PCT/US2014/026224 WO2014160281A2 (en) 2013-03-14 2014-03-13 Method of enhancing delivery of therapeutic compounds to the eye

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019201474A Division AU2019201474A1 (en) 2013-03-14 2019-03-04 Method of enhancing delivery of therapeutic compounds to the eye

Publications (2)

Publication Number Publication Date
AU2014243925A1 AU2014243925A1 (en) 2015-10-08
AU2014243925B2 true AU2014243925B2 (en) 2018-12-06

Family

ID=50687629

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014243925A Ceased AU2014243925B2 (en) 2013-03-14 2014-03-13 Method of enhancing delivery of therapeutic compounds to the eye
AU2019201474A Abandoned AU2019201474A1 (en) 2013-03-14 2019-03-04 Method of enhancing delivery of therapeutic compounds to the eye

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019201474A Abandoned AU2019201474A1 (en) 2013-03-14 2019-03-04 Method of enhancing delivery of therapeutic compounds to the eye

Country Status (6)

Country Link
US (3) US9730888B2 (enExample)
EP (1) EP2968476B1 (enExample)
JP (3) JP6483083B2 (enExample)
AU (2) AU2014243925B2 (enExample)
CA (1) CA2903545C (enExample)
WO (1) WO2014160281A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403260D0 (en) 2014-02-25 2014-04-09 Univ Manchester Treatment of retinal degeneration using gene therapy
RU2019109021A (ru) * 2016-08-29 2020-09-29 Уэйн Стейт Юниверсити Идентификация мутаций в вариантах каналопсина, имеющих улучшенную чувствительность к свету, и способы их применения
CN117695375A (zh) 2016-09-02 2024-03-15 学校法人庆应义塾 视觉功能再生剂或视觉功能降低预防剂
WO2018128412A1 (ko) * 2017-01-06 2018-07-12 경북대학교 산학협력단 혈전-표적성 펩타이드, 페리틴 단편 및 혈전 용해성 펩타이드를 포함하는 융합 펩타이드 및 이의 용도
WO2018181071A1 (ja) * 2017-03-28 2018-10-04 森永乳業株式会社 非コラーゲン性糖タンパク質分解用組成物
KR20220009427A (ko) * 2019-05-17 2022-01-24 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 글리코시드 가수분해효소를 사용하는 망막 세포에 대한 유전자 치료 벡터의 개선된 전달
US11771741B2 (en) 2019-09-13 2023-10-03 Restore Vision Inc. Nucleic acid construct that encodes chimeric rhodopsin
GB202002073D0 (en) * 2020-02-14 2020-04-01 Ucl Business Ltd Horizontal cells
CA3195696A1 (en) * 2020-09-17 2022-03-24 Restore Vision Inc. Composition for treating or preventing diseases, disorders, or conditions associated with endoplasmic reticulum stress or all-trans-retinal, protecting retinal thickness, or suppressing reduction in retinal thickness or progress of reduction in retinal thickness
JP2022184212A (ja) * 2021-05-31 2022-12-13 ユニ・チャーム株式会社 月経血を吸収するための吸収性物品
CN113355309B (zh) * 2021-08-10 2021-11-05 迈威(上海)生物科技股份有限公司 重组截短型人纤维蛋白溶酶制备工艺
CN117100845A (zh) * 2022-10-24 2023-11-24 景泽生物医药(合肥)股份有限公司 重组人奥克纤溶酶在制备治疗脉络膜血管疾病药物中的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052228A2 (en) * 2002-12-06 2004-06-24 Thromb-X Nv Pharmacological vitreolysis
WO2007005856A1 (en) * 2005-06-30 2007-01-11 Ista Pharmaceuticals, Inc. Use of hyaluronidase in combination with plasmin for the induction of posterior vitreous detachment
WO2009067407A2 (en) * 2007-11-19 2009-05-28 Bausch & Lomb Incorporated Compositions of matrix metalloproteinase activating endopeptidases for reducing intraocular pressure, and methods of use thereof
WO2011023805A1 (en) * 2009-08-28 2011-03-03 Thrombogenics N.V. Use of plasmin for the treatment of filtration failure after trabeculectomy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000015822A1 (en) 1998-09-17 2000-03-23 University Of Florida Methods for treatment of degenerative retinal diseases
US20070196350A1 (en) * 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
US8470790B2 (en) 2006-05-04 2013-06-25 Wayne State University Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
EP2451835A1 (en) * 2009-07-10 2012-05-16 ThromboGenics N.V. Variants of plasminogen and plasmin
CN111378020A (zh) 2012-03-05 2020-07-07 韦恩州立大学 通道视蛋白-2(Chop2)突变的鉴定及使用方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052228A2 (en) * 2002-12-06 2004-06-24 Thromb-X Nv Pharmacological vitreolysis
WO2007005856A1 (en) * 2005-06-30 2007-01-11 Ista Pharmaceuticals, Inc. Use of hyaluronidase in combination with plasmin for the induction of posterior vitreous detachment
WO2009067407A2 (en) * 2007-11-19 2009-05-28 Bausch & Lomb Incorporated Compositions of matrix metalloproteinase activating endopeptidases for reducing intraocular pressure, and methods of use thereof
WO2011023805A1 (en) * 2009-08-28 2011-03-03 Thrombogenics N.V. Use of plasmin for the treatment of filtration failure after trabeculectomy

Also Published As

Publication number Publication date
US9730888B2 (en) 2017-08-15
AU2019201474A1 (en) 2019-03-28
US20160038409A1 (en) 2016-02-11
AU2014243925A1 (en) 2015-10-08
JP2019055980A (ja) 2019-04-11
CA2903545A1 (en) 2014-10-02
HK1220625A1 (zh) 2017-05-12
WO2014160281A2 (en) 2014-10-02
JP2016519063A (ja) 2016-06-30
WO2014160281A3 (en) 2015-04-09
US20200268647A1 (en) 2020-08-27
US20180064640A1 (en) 2018-03-08
EP2968476B1 (en) 2021-05-05
JP2021038240A (ja) 2021-03-11
EP2968476A2 (en) 2016-01-20
CA2903545C (en) 2022-09-06
JP6483083B2 (ja) 2019-03-13

Similar Documents

Publication Publication Date Title
AU2014243925B2 (en) Method of enhancing delivery of therapeutic compounds to the eye
US11883463B2 (en) Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
US9968689B2 (en) AAV-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
JP6240067B2 (ja) 光感受性キメラｇｐｃｒタンパク質
US20230159609A1 (en) G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd)
EP3892738A1 (en) G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd)
US20170183385A1 (en) Methods and compositions for red-shifted chromophore substitution for optogenetic applications
HK1220625B (en) A plasmin for use in enhancing delivery of therapeutic compounds to the eyes or for improving vision
US20230338581A1 (en) G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd)
HK40004342A (en) Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
NZ727041A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired